



 Received: 04 Sep 2015 Revised and Accepted: 18 Nov 2015 
ABSTRACT  
Objective: The main objective of this paper was to evaluate the quality of similar (S, n=3) and generic (G, n=3) tablets and compounding capsules 
(C, n=6) containing nimesulide (100 mg).  
Methods: The parameters investigated (weight, nimesulide content, uniformity of dosage units, disintegration, friability and hardness (tablets) and 
dissolution profile) were evaluated against the Brazilian Pharmacopeia and a reference compound (for tablets). Nimesulide content, determined by 
a UV/visible spectrophotometric method, and dissolution test were validated for compounding capsules. 
Results: All formulations had a mean weight coefficient of variation lower than 5%. Three compounding formulations contained less than 95 mg 
nimesulide, with C1 (88.5 mg) also showing a lack of dosage unit uniformity. Disintegration times were lower than 5 min for all samples and 
friability less than 0.5% for all tablet formulations. The hardness of the reference product (25.5N) was lower compared to the other tablet samples 
(30-80.3N). All tablet formulations reached 75% release after 5 min of the dissolution test, but none of the compounding formulations reached the 
minimum 75% release after 45 min, probably due to inadequate excipient composition and amount. On average, excipient accounted for 46.3% of 
the capsule weight (against 74% in tablets), and some of the products did not contain water-soluble substances to promote dissolution.  
Conclusion: The results of this study indicate a lack of quality in compounding nimesulide products, which could jeopardize patients' health and 
treatment.  
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INTRODUCTION 
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most 
widely prescribed medications in the world [1]. Nimesulide (fig. 1) is a 
cyclooxygenase-II selective NSAID derived from sulfonanilide [2]. The 
drug has analgesic, anti-inflammatory and antipyretic effects, and is 
used mainly in the treatment of acute pain, osteoarthritis and primary 
dysmenorrhea [2-4]. 
According to the Biopharmaceutics Classification System (BCS), 
nimesulide is a class II drug, with low solubility and high permeability, 
which means that dissolution is the rate-limiting step for drug 
absorption [4, 5]. The dissolution profile of a drug formulation 
measured in the laboratory is related to its in vivo release, and can 
predict how they are absorbed, assuring appropriate bioavailability 
and therapeutics [5-8]. 
Nimesulide is found in commercial dosage forms such as 
suppositories, drops, suspensions, granules, and tablets. Compounding 
formulation of nimesulide in gelatin capsules is also widely prescribed 
in Brazil due to the advantages of therapeutic individualization, 
combined drugs and lower costs. Compounding pharmacies represent 
an important market sector, which has been expanding in Brazil and 
other countries. This expansion, however, is not always followed by 
quality assurance, potentially affecting the therapeutic efficacy of the 
drug, and thus posing a risk to human health [9-11].  
To ensure the quality of its products, compounding pharmacies, like 
other pharmaceutical product manufacturers, must comply with Good 
Manufacturing Practices, legal requirements, and regulatory 
standards. These pharmacies must have a quality control system 
implemented to offer safe and appropriate products to patients, who 
expect a medication of the same quality as the industrial product, 
approved and supervised by the competent authorities. However, it is 
not always known whether compounding products were 
manufactured by trained personnel, who followed validated processes 
using properly calibrated and cleaned equipment, with ingredients 
obtained from approved sources and whether appropriate laboratory 
testing was performed to verify the compounding drug potency, 
purity, and quality. Furthermore, the shelf-life of compounding 
products is normally not verified to assure their original strength and 
purity over time [11, 12].  
The current Brazilian legislation concerning compounding pharmacies 
includes the control of the raw material and water, and analysis of 
content and dose uniformity of the final product [13]. However, 
dissolution and disintegration tests are not required. This paper reports 
the validation of a dissolution test for compounding capsules containing 
nimesulide 100 mg and a spectrophotometric method for the 
quantification of nimesulide content in the formulations. Compounding 
and industrialized formulations were evaluated for their physical and 
chemical properties with respect to pharmacopeia specifications. 
  
 
Molecular mass: 308.1 g/mol 
pKa: 6.56 
water solubility: 10 µg/ml 
Fig. 1: Nimesulide 
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MATERIALS AND METHODS 
Chemicals 
Nimesulide European Pharmacopoeia reference standard was 
obtained from Fluka® potassium 
phosphate monobasic
 (100% reported purity). Anhydrous 
, sodium hydroxide, phosphoric acid 85%, 
andpolysorbate 80 were purchased from Dinâmica®
Two nimesulide stock solutions were prepared for this work. A stock 
solution at 200 μg/ml prepared in NaOH 0.01 M (SS1), and a stock 
solution at 150 μg/ml prepared in 7.4 pH potassium phosphate 
buffer+tween 80 at 2% (SS2).  
 (São Paulo, 
Brazil). Water was purified by reverse osmosis system. 
Tested formulations 
Similar (S1, S2, S3), generic (G1, G2, G3), and reference (R; Nisulid® 
  
Aché Laboratórios Farmacêuticos, Brazil) tablets containing 
nimesulide 100 mg were obtained commercially. Their compositions 
are described in table 1. The compounding gelatin capsule 
formulations C1, C2 and C3 and their placebo were donated by three 
different pharmacies. C4 and C5 were purchased from two pharmacies 
in Brasilia (Federal District, Brazil) (table 1). 
Table 1: Excipient formulation composition 
Formulation Composition 
R Lactose, magnesium stearate, microcrystalline cellulose, docusate sodium, sodium starch glycolate, hydroxypropyl cellulose, 
hydrogenated vegetable oil. 
G1 Povidone, sodium croscarmellose, lactose, sodium lauryl sulfate, magnesium stearate, microcrystalline cellulose, ethyl alcohol.  
G2 Lactose, microcrystalline cellulose, docusate sodium, magnesium stearate, hydroxypropyl celullose, hydrogenated vegetable oil, 
sodium starch glycolate. 
G3 Microcrystalline cellulose, lactose, docusate sodium, povidone, crospovidone, hydrogenated vegetable oil. 
S1 Sodium lauryl sulfate, colloidal silicon dioxide, lactose, microcrystalline cellulose, magnesium stearate, sodium croscarmellose. 
S2 Lactose, microcrystalline cellulose, sodium starch glycolate, sodium docusate, hydroxypropyl cellulose, hydrogenated vegetable oil, 
magnesium stearate. 
S3 Microcrystalline cellulose, sodium croscarmellose, magnesium stearate, colloidal silicon dioxide, hydrogenated vegetable oil, 
lactose, povidone. 
C1 Stearic acid, sodium croscarmellose, colloidal silicon dioxide, magnesium silicate, microcrystalline cellulose. 
C2 Sodium lauryl sulfate, microcrystalline cellulose, starch. 
C3 Sodium lauryl sulfate, sodium croscarmellose, colloidal silicon dioxide, starch, microcrystalline cellulose. 
R= reference formulation; G= generic formulation; S= similar formulation; C= compounding formulation 
 
Nimesulide determination  
Nimesulide content was determined according to the Brazilian 
Pharmacopeia (2010) for tablet formulations. The method was 
validated in this study for capsule formulations. 
Twenty tablet units (R, G and S formulations) or the content of 20 
capsules (C formulations) were homogenized, a sample containing 
approximately 100 mg of nimesulide transferred to a 100 ml 
volumetric flask, the volume completed with 0.01 M NaOH, the 
solution filtered using an 80 g/cm² filter (Prolab®
To determine the content of nimesulide in the dissolution test, the 
withdrawn aliquots were filtered, 1 ml diluted to 100 ml with water, 
and nimesulide content determined against a calibration curve 
prepared in water from SS2 (0.45 to 2.25 μg/ml). 
), and an aliquot 
diluted with 0.01 M NaOH to a final concentration of 2 μg/ml. Three 
aliquots of this final solution were taken to determine the content of 
nimesulide using a UV/Vis spectrophotometer (1650PC; Shimadzu®) 
at 392 nm against a nimesulide calibration curve in 0.01 M NaOH (0.4 
to 3.0 μg/ml) prepared from SS1. 
Method validation for nimesulide in gelatin capsules 
(compounding formulations) 
All validation parameters were evaluated according to International 
Conference on Harmonization guidelines [14].  
Linearity of the spectrometric response was evaluated for nimesulide 
calibration curves at 0.4, 1.0, 1.6, 2.0, 2.4 and 3.0 μg/ml prepared in 
0.01M NaOH from SS1, and at 0.45, 0.75, 1.2, 1.5, 1.8 and 2.25 μg/ml 
prepared in water from SS2. Each solution was prepared in triplicate. 
The absorption at 392 nm of the resulting solutions was measured.  
Specificity was evaluated by comparing the spectrum of the C1, C2 and 
C3 excipients and excipient plus gelatin capsule with the spectrum of 
nimesulide standard solutions at 2 and 1.5 μg/ml, prepared in 0.01 M 
NaOH (from SS1) and in water (from SS2), respectively. 
Spectrophotometric scans for each solution were obtained from 
300 to 600 nm. 
Precision was assessed by estimating repeatability and intermediate 
precision. Repeatability was evaluated through the coefficient of 
variation (CV) from the recovery data of formulations C1, C2 and C3 (6 
replicates for each) prepared at a theoretical concentration of 2 μg/ml 
in 0.01 M NaOH (from SS1) and of 1.5 μg/ml in water (from SS2). 
Intermediate precision was evaluated with data obtained on two 
different days.  
Accuracy was assessed by recovery data. Known amounts of the 
nimesulide standard were added to solutions of the C1, C2 and C3 
excipients at final concentrations of 1.6, 2.0 and 2.4 μg/ml in 0.01 M 
NaOH (80, 100 and 120% of the nominal assay of nimesulide), and at 
1.2, 1.5 and 1.8 μg/ml in water (from SS2). The absorption at 392 nm 
was measured, and percentages recovered at each concentration level 
calculated.  
Robustness of the nimesulide determination method was assessed by 
checking the results using 80 or 200 g/cm² filters to prepare the 0.01 
M NaOH solutions. Stability of the standard solution at 2 μg/ml with 
0.01 M NaOH was also evaluated for a 4-hour period.  
Robustness of the dissolution method was assessed using dissolution 
medium prepared with two different potassium phosphate brands and 
nimesulide standard solutions in water (prepared from SS2). 
Withdrawn aliquots were filtered with 80 or 200 g/cm² filters. 
Stability of the standard solution diluted with water at concentration 
of 1.5 μg/ml was evaluated for a 4-hour period. 
Uniformity of dosage units 
The assessment of this parameter was based on the drug content 
results and individual weight of 10 units for each product. The test 
estimated the drug content in each unit. An acceptance value (AV) was 
calculated as an approval criterion, according to Brazilian 
Pharmacopeia specifications [15]. This value had to be below the 
reference limit of 15.0. When this was not the case, it was necessary to 
carry out the test with an additional 20 units and the AV calculated 
with all 30 units. Table 2 shows the equations used in these 
calculations. 
Disintegration of tablet formulations 
Disintegration time was evaluated in an Ethic technology model 301-1 
(Brazil) disintegrator using six units of each formulation and purified 
Silva et al. 
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water at 37±1ºC as immersion media [15-17]. Disintegration time was 
reached when all six units were disintegrated in the tester.  
Friability and hardness of tablet formulations 
Friability was tested with 20 accurately weighted tablets and placed in the 
drum of a friabilator (Nova Ética® 300 apparatus). The tablets were rotated 
at 25 rpm for 4 min, removed, accurately re-weighted, and the percentage 
weight loss calculated [16]. Hardness (Nova Ética®
Dissolution tests were conducted in a Nova Etica
 298-AT apparatus) was 
individually assessed for 10 tablets of each formulation and the results 
expressed as mean values in Newtons (N) [15, 16]. 
Dissolution test  
®
Tablet dissolution profile comparison 
 299/6 apparatus, using 
basket for capsules or paddle for tablet formulations, and 900 ml of 7.4 pH 
potassium phosphate buffer+tween 80 at 2% as dissolution medium. 
Twelve units of each formulation were used in each test. The tests were 
conducted at 37 °C at 75 rpm, with 5 ml samples taken at 5, 10, 15, 20, 30 
and 45 min (with medium dissolution replacement) after test initiation, 
and the nimesulide content determined spectrophotometrically. 
In order to compare the dissolution profiles obtained for the tablet 
formulations, the difference factor (f1), the similarity factor (f2), and 
dissolution efficiency (DE) were determined. The DE was calculated 
from the area under the dissolution curve at time t i
The f
 (measured using 
the trapezoidal rule) and expressed as a percentage of the area of the 
rectangle described by 100% dissolution at the same time [18, 19]. 
Statistical treatments of DE results were based on variance analysis 
and t-test.  
1 factor measures the percent error between two dissolution 
curves over all time points. It is zero when the compared profiles are 
identical and increases proportionally with the dissimilarity between 
the two dissolution profiles. The f2 factor is a logarithmic 
transformation of the sum-squared error of differences between the 
compared products over all time points (table 2). It is 100 when the 
profiles are identical and tends to 0 as the difference increases. Two 
dissolution profiles are considered similar if f1 is between 0 and 15 
and f2
 
 is between 50 and 100 [18, 19]. 
Table 2: Equations used to the calculation of f1 and f2
Definition 
 values and uniformity of dosage units 
Equations Legend 
Individual drug 
content in each 
unit 





𝑤𝑤𝑖𝑖: Individual weight of each unit; A: drug content (%); W: mean weight 
(n=20). 
Acceptance value 𝐴𝐴𝐴𝐴 = [𝑀𝑀 −  𝑋𝑋�] + 𝑘𝑘𝑘𝑘 If 98,5% ≤ 𝑋𝑋�≤ 101,5% M=𝑋𝑋� 
If 𝑋𝑋�<98,5% M=98,5% 
If 𝑋𝑋�>101,5% M=101,5% 
𝑋𝑋�: mean of the individual drug content (n=10 or n=30); 𝑘𝑘: acceptability 
constant; s: standard deviation. 
f
𝑓𝑓1 =
∑ [𝑅𝑅𝑡𝑡 − 𝑇𝑇𝑡𝑡]𝑛𝑛𝑡𝑡=1
∑ 𝑅𝑅𝑡𝑡𝑛𝑛𝑡𝑡=1
× 100 1
 n: number of units; 𝑅𝑅𝑡𝑡 : percentage of dissolved drug from reference 
product in each time point t; 𝑇𝑇𝑡𝑡 : percentage of dissolved drug from test 
product in each time point t. f











RESULTS AND DISCUSSION 
Method validation for capsule formulations 
Currently, the pharmacopeia method to measure nimesulide 
concentration is only available for tablet formulation, and in this study 
the same method was validated for capsule formulations, used in 
compounding pharmacies. The method was validated using nimesulide 
dissolved in 0.01 M NaOH (to measure the concentration in the 
formulation) and buffer/water (concentration after the dissolution 
test). Nimesulide calibration curves prepared in both media showed 
correlation coefficients higher than 0.999 for all replicates (n=3). 
Specificity of nimesulide measurement in the spectrophotometer was 
shown in the range of 300 to 600 nm (fig. 2), with no significant 
absorption due to the excipient (0.01 M NaOH) and the excipient plus 
capsules (in 7.4 pH potassium phosphate buffer).  
The precision of the spectrophotometric measurement was shown 
through the repeatability (n=6) and intermediate precision (n=12), 
with CV values below 5% in both cases. The method showed to be 
accurate, with recovery within the accepted range (95 to 105%) for all 
3 concentration levels and different combinations of excipients. 
The method was shown to be robust since the results of nimesulide 
content were not significantly different when the final solution was 
filtered using an 80 or 200 g/cm² filter paper (data not shown). 
Stability of the reference standard solutions prepared in 0.01 M NaOH 
and potassium phosphate buffer was confirmed for a 4-hour period, 
with variations in concentration of the solutions of 0.9 and 0.5%, 
respectively (data not shown).  
Characteristics of nimesulide formulations 
Table 3 shows the physical properties of the formulations investigated 
in this study. In all cases, the CV of the mean weight (n=20) was lower 
than 5%. According to the Brazilian Pharmacopeia (2010), for tablets 
with a mean weight higher than 250 g, no more than two in 20 units 
tested should have a variation higher than±5% the mean weight, and 
for compounding capsules weighing lower than 300 mg, this variation 
should not exceed±10%. 
 
 
Fig. 2: Absorption spectra of nimesulide standard and excipients, 
in 0.01 M NaOH (A) and excipient plus capsules from 
compounding formulations solutions in potassium phosphate 
buffer (B) 
Silva et al. 
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All formulations were within these parameters, indicating weight 
homogeneity within the product lots. On average, the excipient 
accounted for 73.9% of the total weight for tablet formulations (67.8-
75.2%), and 46.3% for compounding, showing a large variation among 
the formulations (17.1 % for C1 to 65.4% for C3).  
Most likely, the results for the compounding capsules are due to 
the excipient composition in formulations, which is a key 
parameter to guarantee disintegration and dissolution of solid 
dosage forms (table 1), an issue that will be discussed further in 
this paper. 
 
Table 3: Characteristics of the nimesulide formulations 
Formulation Weight, mg (CV, %) Nimesulide, mg (CV, %)a Disintegration time b Friability, % Hardness, N (CV, %)a c 
R 403.7 (0.37) 102.1 (1.11) 1’41” 0.33 25.5 (5.1) 
G1 405.1 (2.4) 103.6 (0.63)  2’52” 0.22 73.2 (12.8) 
G2 399.5 (0.6) 100.9 (0.53) 56” 0.21 30.0 (13.1) 
G3 400.6 (2.0) 99.4 (0.75)  1’30” 0.04 76.5 (6.4) 
S1 399.4 (2.0) 99.0 (1.04)  1’16” 0.12 80.3 (20.9) 
S2 392.0 (0.78) 97.9 (0.66) 1’16” 0.13 77.0 (10.5) 
S3 298.6 (1.1) 95.9 (0.50) 1’15” 0.33 72.3 (19.3) 
C1 107.3 (2.8) 88.9 (0.62) 1’15” - - 
C2 170.5 (2.8) 94.3 (0.53) 2’25” - - 
C3 277.3 (1.9) 96.0 (1.05) 1’50” - - 
C4 259.3 (2.7) 91.9 (0.63) 2’33” - - 
C5 169.5 (4.1) 102.1 (1.04) 2’41” - - 
CV= coefficient of variation; a20 units; b mean of three determinations; c
 
10 units; R= reference formulation; G= generic formulation: S= similar 
formulation; C= compounding formulation 
Mean nimesulide content (n=3) in tablet formulations ranged from 
95.9 to 103.6 mg (table 3), within the maximum ±5% deviation range 
of the reported label content (100 mg), specified in the Brazilian 
Pharmacopoeia [15]. Three compounding formulations (C1, C2 and 
C4) did not comply with the Pharmacopeia, with respective values of 
88.9%, 94.3% and 91.9%. It is possible to correlate this observed 
quality deviation of the compounding formulations with inaccurate 
weighting, uncalibrated balances, and operators with the lack of 
proper training, or loss of the drug during the encapsulation process. 
Furthermore, the inadvertent acquisition of low-quality raw 
ingredients by the compounding pharmacy can be a very important 
source of products with inadequate active content. 
The result of the uniformity of dosage unit test was unsatisfactory for 
formulation C1, with a final calculated AV of 19.7, higher than the 
pharmacopeia specification (lower than 15.0). This deviation may be 
due to lack of homogenization of the active ingredient and excipient 
mixture, a major step during the manipulation process to yield the 
same amount of drug in every single unit of the product. Uniformity of 
content in solid dosage forms is a key parameter, especially with 
regard to compounding pharmacies, due to component segregation, 
which can decrease homogeneity of the blended powder. It is known 
that manipulation processes vary amongst different establishments 
[20], and it is important to validate the process and apply Good 
Manufacture Practices in order to yield quality products. 
Disintegration times were lower than 5 min for all formulations tested 
(table 3), in agreement with the Pharmacopeia that specifies a 
maximum of 30 min for tablets, and 45 min for capsules [15]. 
Friability, which indicates the ability of the tablets to withstand 
abrasion in packing, handling and transporting (in % of mass loss), 
was less than 0.5% for all tablet formulations, within the Brazilian 
(maximum of 1.5%) and the US (maximum of 1.0%) pharmacopeia 
specifications. Hardness, which measures the strength of the tablet to 
withstand pressure, ranged from 30 to 80 N. Although this is only an 
informative test [16], there was a large variation among the tablet 
formulations, with the reference product presenting the lowest value 
and variability (25.5 N, CV of 5.1%), and could reach 80.3 N (CV of 
20.9%) for a similar formulation (table 3).  
Comparing the therapeutic performance of two pharmaceutical products 
containing the same drug represents an approach to evaluate possible 
inter changeability between innovator and similar formulations [22]. 
The absorption of a drug after oral administration depends on the 
release from a dosage form, dissolution under physiological conditions 
and intestinal permeability [23]. As the first and second stages are 
critical in the absorption process, in vitro dissolution is a relevant 
approach to predict in vivo therapeutic performance of a pharmaceutical 








Fig. 3: Dissolution profiles of nimesulide 100 mg in the reference 
and generic tablets (A), reference and similar tablets (B) and in 
the compounding formulations (C) 
Silva et al. 
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Dissolution profiles of the tablet formulations are shown in fig. 3 (A and 
B). According to the Brazilian Pharmacopeia, at least 75% of the drug 
should be released from the tablet during the 45 min of the test [15]. In 
this study, all tested tablet formulations reached 75% release after 5 min 
of the assay. 
A statistical comparison between two dissolution profiles has the purpose 
of testing the possibility of interchange ability between the reference, and a 
similar or generic product [22]. The results in table 3 show that the 
dissolution efficiency (DE) of formulations S3, G2 and G3 were statistically 
different from formulation R (*P<0.005). Two dissolution profiles are 
considered similar if f1 is between 0 and 15, and f2 is between 50 and 100. 
The f2 factor was not calculated for formulations G1, G2, G3, S1 and S2 due 
to the fast release of the drugs (over 85% within 15 min of the assay), 
when f2 loses its discriminatory power [17]. Table 4 shows that only 
formulation S3 was not similar to formulation R, due to a low f2 (47.2). 
Although the f1 and f2
Fig. 3C shows the dissolution profiles of the compounding 
formulations. None of the tested formulations had the minimum 
release of 75% after 45 min of the assay, probably due to the excipient 
composition. In order to improve the dissolution of a poorly water-
soluble drug such as nimesulide, the use of an adequate excipient 
blend is recommended [26-28], and should include wetting agents, 
such as sodium lauryl sulfate, and water-soluble diluents, like lactose.  
 factors are useful parameters for comparing two 
formulations, a larger number of batch pairs should be used in the study to 
obtain meaningful results [24, 25]. 
The formulation that showed the most unsatisfactory performance 
was C2, for which only 30% of the drug was released after 45 min. C2 
contains sodium lauryl sulfate, microcrystalline cellulose, and starch 
(table 1), but lacks a water-soluble substance to act as the wetting 
agent (sodium lauryl sulfate) in order to promote dissolution. 
 
Table 4: Dissolution efficiency (DE; n=12) difference factor (f1) and similarity factor (f2
Product 
) for tablet formulations 
DE (mean±sd) f f1 2 
R 83.9±1.48 - - 
G1 86.5±2.68 2.75 - 
G2 85.4±3.3* 7.65 - 
G3 76.7±0.83* 5.63 - 
S1 85.3±1.67 3.37 - 
S2 89.1±2.33 3.58 - 
S3 87.7±2.67* 10.84 47.24 
sd= standard deviation; * significantly different from the reference compound R (*P<0.005) 
 
Although products C1 and C3 contain some substances that increase 
poor water-soluble drug dissolution (sodium lauryl sulfate and sodium 
croscarmellose), the formulation performance still did not comply 
with pharmacopeia specifications (about 50% release after 45 min of 
the assay; fig. 3C). This indicates that the proportion of the excipients 
in the formulation was probably not adequate to obtain an optimal 
dissolution of the capsule.  
Although the excipient composition of C4 and C5 were not available for 
this study, it is possible to assume that the C4 formulation contained 
suitable excipients that promoted nimesulide release and improved its 
dissolution. This product had the most satisfactory dissolution 
performance among the capsules. Furthermore, as previously shown, 
the proportion of excipients to the total compounding formulation 
weight was low in most cases (17% for C1), which might also have had 
a significant impact on the dissolution profiles. The selection of 
suitable excipients in an appropriate proportion is critical for reaching 
satisfactory dissolution performance and, therefore, adequate 
bioavailability. 
CONCLUSION 
Nimesulide is a BCS class II drug and, since dissolution in Vitro 
represents the rate-limiting step for drug bioavailability, it is of major 
importance that dissolution tests are conducted during formulation 
development and quality control of the final product. Inadequate drug 
dissolution greatly compromises the expected effect on the organism, 
resulting in poor therapeutic efficacy, and may represent a risk to a 
patient's health. The results of this study showed that none of the 
tested compounding formulations showed an adequate dissolution 
profile, probably due to inadequate excipient composition. Brazilian 
legislation for compounding products should include dissolution tests 
to assure the therapeutic efficacy of the final product. Furthermore, 
compounding establishments should be closely monitored to ensure 
their compliance with the regulation.  
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